Company / Capital Expenditures
Spyre Therapeutics, Inc. Capital Expenditures History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2024
5-year range
$0 / $4.3M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#190 of 194
Health Care
What the data says
Declined from $4M to $0 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194
▼
Key checks
Key Insights
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0 | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $4.3M | +646.9% |
| FY2021 | $573.0K | +35.8% |
| FY2020 | $422.0K | -31.8% |
| FY2019 | $619.0K | +192.0% |
| FY2018 | $212.0K | -65.8% |
| FY2017 | $619.0K | +192.0% |
| FY2016 | $212.0K | +1.9% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026